CTIS2024-511125-61-00招募中1 期
An open-label, multi-center rollover protocol for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib as single agent or in combination with other investigational treatments - CLEE011X2X01B
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Patient is currently enrolled in an eligible Novartis-sponsored ribociclib (LEE011) study and is receiving ribociclib as single agent or in combination with other investigational treatments., Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator., Patient has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
排除标准
- •Patients who have permanently discontinued from ribociclib (LEE011) in the parent protocol for any reason, Patients who do not meet parent protocol criteria to continue study treatment.
研究者
相似试验
进行中（未招募）
1 期
A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agentsEUCTR2016-000293-37-FRovartis Pharma Services AG40
进行中（未招募）
1 期
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatmentsDifferent types of advanced cancerMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028997Term: Neoplasm malignant Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-508841-42-00ovartis Pharma AG119
招募中
2 期
An open-label, multi-center rollover protocol for patients
who have participated in a Novartis-sponsored ribociclib
(LEE011) study and are continuing to benefit from
ribociclib as single agent or in combination with other
investigational treatments2024-511125-61-00Novartis Pharma AG1
招募中
不适用
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatmentssolid cancer(s)malignancy10027655NL-OMON51829ovartis1
进行中（未招募）
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.Biliary atresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10004654Term: Biliary atresia, congenitalSystem Organ Class: 100000004850EUCTR2014-004693-42-FIIntercept Pharmaceuticals, Inc.72